#USA #New York #EsoGuard #EsophagealCancer #LucidDiagnostics

Overview of Lucid Diagnostics' Landmark Study

Lucid Diagnostics Inc., a trailblazer in cancer prevention medical diagnostics, has published what is now recognized as the largest real-world clinical study focusing on nonendoscopic testing for esophageal precancer, involving a staggering 12,000 patients. Utilizing their innovative EsoGuard® Esophageal DNA Test and the EsoCheck® device, this study has significant implications for the timely detection of precancerous conditions in at-risk individuals.

Significance of the Study

The peer-reviewed manuscript, titled "Non-Endoscopic Screening for Barrett's Esophagus Using a DNA Methylation-Based Assay Real-World Experience in 11,991 Patients," was featured in the journal Diagnostics. This publication represents a substantial step forward in understanding and improving esophageal cancer screening practices. The findings indicate that the EsoCheck device not only allows for rapid cell collection but also demonstrates high tolerance levels among patients, achieving efficiency across the board—even with operators who are newly trained.

Study Findings

Conducted between January 2023 and June 2024, the study encompassed a diverse cohort of 11,991 participants, each of whom displayed various clinical risk factors. Here are some of the key results:

• - Success Rates: The EsoCheck cell collection proved successful in 95% of the cases.
• - Speed of Collection: The average duration for sample collection was less than two minutes, showcasing an efficient process.
• - Patient Tolerance: Notably, 82% of respondents reported low discomfort levels, with only a minimal 0.2% rating their experience as painful.
• - Test Recommendation: An impressive 96% expressed they would recommend the test to others, and 95% stated they would opt for it again if deemed necessary.

Insights from Leadership

Dr. Lishan Aklog, the Chairman and CEO of Lucid, expressed his enthusiasm for the study's results, stating, "These findings provide compelling real-world evidence supporting the feasibility of large-scale implementation of EsoGuard testing." He emphasized the importance of Medicare's nationwide reimbursement for EsoGuard, heralding a critical advancement in the commercial rollout of the testing across varied clinical environments.

Dr. Victoria T. Lee, Lucid's Chief Medical Officer, also shared her confidence in the technology's performance, noting, "The high cell collection success rate across operators, along with patient satisfaction and minimally invasive procedure times, reinforce the potential for expansive access to esophageal precancer testing for those at risk."

Lucid Diagnostics: Company Background

Lucid Diagnostics is dedicated to combating the risks faced by millions of patients suffering from gastroesophageal reflux disease (GERD) or chronic heartburn, conditions that significantly increase the chances of developing esophageal precancer and cancer. The EsoGuard test, combined with the EsoCheck device, underscores the company's mission to facilitate early detection and ultimately reduce cancer-related deaths through proactive healthcare measures.

As Lucid continues to innovate within the field of cancer diagnostics, it remains focused on enhancing patient outcomes and accessibility to essential testing. For further details about their products, visit Lucid Diagnostics and to learn about their parent company, PAVmed.

This landmark study lays a strong foundation for the future of esophageal cancer screening and encourages an industry-wide shift towards more efficient and patient-centered diagnostic practices.